Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
FDMT 4D Molecular Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: FDMT
Price (delayed)
$3.83
Market cap
$177.42M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.18
Enterprise value
$67.75M
4DMT is a clinical-stage company harnessing the power of directed evolution for targeted gene therapies. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector
Highlights
The company's debt has surged by 68% YoY but it fell by 3.1% QoQ
The gross profit has dropped by 100% year-on-year and by 38% since the previous quarter
FDMT's revenue has dropped by 100% year-on-year and by 38% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Key stats
What are the main financial stats of FDMT
Market
Valuations
Earnings
Shares outstanding
46.32M
Market cap
$177.42M
Enterprise value
$67.75M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.38
Price to sales (P/S)
9,282.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,945.67
Revenue
$23,000
Gross profit
$23,000
Operating income
-$203.33M
Net income
-$176.44M
EBIT
-$176.44M
EBITDA
-$169.57M
Free cash flow
-$156.96M
Per share
Balance sheet
Liquidity
EPS
-$3.18
EPS diluted
-$3.18
Free cash flow per share
-$2.82
Book value per share
$10.14
Revenue per share
$0
TBVPS
$9.25
Total assets
$515.73M
Total liabilities
$46.01M
Debt
$23.85M
Equity
$469.72M
Working capital
$305.67M
Debt to equity
0.05
Current ratio
12.36
Quick ratio
11.95
Net debt/EBITDA
0.65
Margins
Efficiency
Dividend
EBITDA margin
-737,278.3%
Gross margin
100%
Net margin
-767,126.1%
Operating margin
-884,026.1%
Return on assets
-30.7%
Return on equity
-33.3%
Return on invested capital
-43.5%
Return on capital employed
-36.1%
Return on sales
-767,126.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
FDMT stock price
How has the 4D Molecular Therapeutics stock price performed over time
Intraday
-1.03%
1 week
10.37%
1 month
1.86%
1 year
-84.56%
YTD
-31.24%
QTD
18.58%
Financial performance
How have 4D Molecular Therapeutics's revenue and profit performed over time
Revenue
$23,000
Gross profit
$23,000
Operating income
-$203.33M
Net income
-$176.44M
Gross margin
100%
Net margin
-767,126.1%
The gross profit has dropped by 100% year-on-year and by 38% since the previous quarter
FDMT's revenue has dropped by 100% year-on-year and by 38% since the previous quarter
The company's net margin has shrunk by 76% QoQ
The operating margin has plunged by 74% from the previous quarter
Price vs fundamentals
How does FDMT's price correlate with its fundamentals
Growth
What is 4D Molecular Therapeutics's growth rate over time
Valuation
What is 4D Molecular Therapeutics stock price valuation
P/E
N/A
P/B
0.38
P/S
9,282.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,945.67
4D Molecular Therapeutics's EPS has decreased by 30% YoY and by 7% from the previous quarter
The stock's P/B is 82% below its 5-year quarterly average of 2.1 and 58% below its last 4 quarters average of 0.9
The company's equity fell by 22% YoY and by 8% QoQ
FDMT's revenue has dropped by 100% year-on-year and by 38% since the previous quarter
The P/S is 28% lower than the last 4 quarters average of 12833.2
Efficiency
How efficient is 4D Molecular Therapeutics business performance
4D Molecular Therapeutics's ROS has plunged by 76% from the previous quarter
The return on invested capital rose by 33% year-on-year but it has declined by 8% since the previous quarter
The return on equity has declined by 25% year-on-year and by 16% since the previous quarter
The ROA has contracted by 24% YoY and by 15% from the previous quarter
Dividends
What is FDMT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for FDMT.
Financial health
How did 4D Molecular Therapeutics financials performed over time
FDMT's quick ratio has shrunk by 63% YoY and by 18% QoQ
4D Molecular Therapeutics's current ratio has shrunk by 62% YoY and by 17% QoQ
The company's debt is 95% lower than its equity
FDMT's debt to equity has surged by 150% year-on-year
The company's debt has surged by 68% YoY but it fell by 3.1% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.